Cardiovascular Disease and Risk Management

被引：181

作者：

不详

机构：

来源：

DIABETES CARE | 2015年 / 38卷

关键词：

TYPE-2; DIABETES-MELLITUS; CORONARY-HEART-DISEASE; CONVERTING-ENZYME-INHIBITORS; VENTRICULAR SYSTOLIC FUNCTION; LOWERING LDL CHOLESTEROL; BLOOD-PRESSURE CONTROL; 14; RANDOMIZED-TRIALS; PRIMARY PREVENTION; STATIN THERAPY; ASYMPTOMATIC PATIENTS;

D O I：

10.2337/dc15-S011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：S49 / S57

页数：9

共 78 条

[31] Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels -: Subgroup analyses in the cholesterol and recurrent events (CARE) trial [J].

Goldberg, RB ;

Mellies, MJ ;

Sacks, FM ;

Moyé, LA ;

Howard, BV ;

Howard, WJ ;

Davis, BR ;

Cole, TG ;

Pfeffer, MA ;

Braunwald, E .

CIRCULATION, 1998, 98 (23) :2513-2519

[32] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].

Granger, CB ;

McMurray, JJV ;

Yusuf, S ;

Held, P ;

Michelson, EL ;

Olofsson, B ;

Östergren, J ;

Pfeffer, MA ;

Swedberg, K .

LANCET, 2003, 362 (9386) :772-776

[33] Prognostic Value of Coronary Computed Tomographic Angiography in Diabetic Patients Without Known Coronary Artery Disease [J].

Hadamitzky, Martin ;

Hein, Franziska ;

Meyer, Tanja ;

Bischoff, Bernhard ;

Martinoff, Stefan ;

Schoemig, Albert ;

Hausleiter, Joerg .

DIABETES CARE, 2010, 33 (06) :1358-1363

[34] Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem [J].

Hayward, Rodney A. ;

Hofer, Timothy P. ;

Vijan, Sandeep .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (07) :520-530

[35] Influence of Time of Day of Blood Pressure-Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes [J].

Hermida, Ramon C. ;

Ayala, Diana E. ;

Mojon, Artemio ;

Fernandez, Jose R. .

DIABETES CARE, 2011, 34 (06) :1270-1276

[36]

James PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI 10.1001/jama.2013.284427

[37] Reporting rate of Rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin [J].

Jones, PH ;

Davidson, MH .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (01) :120-122

[38]

Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X

[39] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[40] Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it "Ok" to Discontinue? [J].

Kezerashvili, Anna ;

Marzo, Kevin ;

De Leon, Joshua .

CURRENT CARDIOLOGY REVIEWS, 2012, 8 (01) :77-84

← 1 2 3 4 5 6 7 8 →